Logo do repositório
 
Publicação

Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose

2022Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorKrzywicka, Katarzyna
dc.contributor.authorvan de Munckhof, Anita
dc.contributor.authorZimmermann, Julian
dc.contributor.authorBode, Felix J.
dc.contributor.authorFrisullo, Giovanni
dc.contributor.authorKarapanayiotides, Theodoros
dc.contributor.authorPötzsch, Bernd
dc.contributor.authorSánchez van Kammen, Mayte
dc.contributor.authorHeldner, Mirjam R.
dc.contributor.authorArnold, Marcel
dc.contributor.authorKremer Hovinga, Johanna A.
dc.contributor.authorFerro, José
dc.contributor.authorde Sousa, Diana Aguiar
dc.contributor.authorCoutinho, Jonathan M.
dc.date.accessioned2022-05-03T14:09:24Z
dc.date.available2022-05-03T14:09:24Z
dc.date.issued2022
dc.description© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.pt_PT
dc.description.abstractCerebral venous thrombosis (CVT) is the most common and severe manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), which is a rare side effect of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca/Oxford). The absolute risk of VITT and VITT-related CVT is estimated at 20 and 8 per million first doses of ChAdOx1 nCoV-19, respectively. So far, no definite VITT cases occurring after a second ChAdOx1 nCoV-19 vaccine dose have been reported, raising the question of whether VITT only occurs after a first dose. Two pharmacovigilance studies reported cases of thrombosis with thrombocytopenia after a second ChAdOx1 nCoV-19 dose, but because of lack of clinical data, none of these could be classified as VITT. Knowledge on whether VITT can occur after a second ChAdOx1 nCoV-19 dose is relevant for clinicians and policymakers, especially in low- and middle-income countries, which are currently the main users of adenovirus-based vaccines. We used data from the “CVT after SARS-CoV-2 vaccination” registry to identify VITT-related CVT cases occurring after a second ChAdOx1 nCoV-19 dose. Details of this registry have been published. Briefly, this ongoing study collects data on patients with CVT with symptom onset ≤28 days from SARS-CoV-2 vaccination, regardless of the type and dose of vaccine. The study is endorsed by the European Academy of Neurology and the European Stroke Organization. Investigators are instructed to report consecutive cases from their hospitals. The ethical review board of the Academic Medical Centre issued a waiver of formal approval for this observational study. Each center obtained local permission to carry out the study and acquired informed consent for the use of pseudonymized care data according to national law. We used the case definition criteria of the United Kingdom expert hematology panel to classify cases as definite, probable, possible, or unlikely VITT after ChAdOx1 nCoV-19 administration among CVT cases reported until 1 December 2021.pt_PT
dc.description.sponsorshipThis work was supported by The Netherlands Organisation for Health Research and Development (ZonMw, grant number 10430072110005) (J.M.C.) and the Dr. C. J. Vaillant Foundation (J.M.C.).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBlood. 2022 Apr 28;139(17):2720-2724pt_PT
dc.identifier.doi10.1182/blood.2021015329pt_PT
dc.identifier.eissn1528-0020
dc.identifier.issn0006-4971
dc.identifier.urihttp://hdl.handle.net/10451/52654
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherASH Publicationspt_PT
dc.relation.publisherversionhttps://ashpublications.org/bloodpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.titleCerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dosept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2724pt_PT
oaire.citation.issue17pt_PT
oaire.citation.startPage2720pt_PT
oaire.citation.titleBloodpt_PT
oaire.citation.volume139pt_PT
person.familyNameMorão Cabral Ferro
person.familyNameAguiar de Sousa
person.givenNameJosé Manuel
person.givenNameDiana
person.identifier574112
person.identifier.ciencia-id6F16-7E25-7AAF
person.identifier.ciencia-id571C-121A-5CCB
person.identifier.orcid0000-0002-2343-9097
person.identifier.orcid0000-0002-6702-7924
person.identifier.ridJ-4105-2013
person.identifier.scopus-author-id55781226000
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9a568ce6-d218-44fc-982c-0ffe7bffc197
relation.isAuthorOfPublication1d984575-dd95-4ca1-9092-bf6f9914ba63
relation.isAuthorOfPublication.latestForDiscovery9a568ce6-d218-44fc-982c-0ffe7bffc197

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Cerebral_venous.pdf
Tamanho:
735.36 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais